-
Dr. Hao Zeng Shares the West China Hospital Team’s Experience in Treating Special Types of Renal Cancer and Clinical Exploration
Renal cancer is one of the three major tumors of the urinary system. Several large phase III studies on combined targeted and immunotherapy have been successful, and the 2024 update of the CSCO renal cancer diagnosis and treatment guidelines has officially brought first-line treatment for advanced renal cancer into the era of combined targeted and…
-
Interview with Dr. Swaminathan P iyer at the EHA 2024: Exploring Breakthroughs in Secondary HLH Treatment with ELA26
At this year’s European Hematology Association (EHA) conference, we had the opportunity to speak with Dr. Swaminathan P iyer, Professor of Medicine at MD Anderson Cancer Center, about the groundbreaking phase I study on ELA26 for secondary hemophagocytic lymphohistiocytosis (HLH). Dr. Iyer shared the promising data from the treatment-naive cohort, which showed a remarkable 100%…
-
-
ESMO 2024丨Dr. Silke Gillessen: Radium-223 Combined with Enzalutamide Offers New Hope for Bone Metastatic mCRPC Patients
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13 to 17 in Barcelona, Spain. Key research in the field of urologic oncology garnered much attention, particularly in the area of prostate cancer. The EORTC-GUCG 1333/PEACE-3 clinical trial (LBA1 – A randomized multicenter open label phase III trial comparing enzalutamide…
-
CSCO 2024 | Dr. Yongmei Yin: A New Era in HER2-Positive Breast Cancer Treatment—From Targeted Therapy to ADC Breakthroughs
With the rapid advancement of medical technology, the treatment of HER2-positive breast cancer has entered a new chapter. In recent years, the emergence of anti-HER2 targeted drugs and new ADC (Antibody-Drug Conjugates) drugs has not only enriched the treatment options but also brought unprecedented hope to patients with HER2-positive breast cancer. At CSCO 2024, Oncology…
-
CUA 2024丨Academician Xu Zhang Shares Conference Highlights and New Advances in Prostate Cancer Radioligand Therapy, and Looks Ahead at the Future Deve
The 31st Urology Academic Conference, organized by the Chinese Medical Association and the Chinese Urological Association (CUA), took place from September 19 to 22, 2024, at the National Convention Center in Tianjin. The conference brought together leading urology experts to showcase the latest clinical research and surgical advancements. After the event, Urology Frontier invited Academician…
-
ESMO 2024丨Dr. Liangyou Gu: Application and Development of Neoadjuvant Therapy in Renal Cancer with Venous Tumor Thrombus
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting took place from September 13 to 17 in Barcelona, Spain. At the event, Dr. Liangyou Gu from the Urology Department of Chinese PLA General Hospital shared findings from the Phase II NEOTAX study on neoadjuvant therapy for renal cancer patients with venous tumor thrombus. The…
-
CSCO 2024 | Academician Binghe Xu: Advancing China’s Clinical Oncology Research with Innovative Drug Development
The 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting, jointly hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, took place from September 25 to 29, 2024, in Xiamen. During this prestigious event, CSCO awarded Academician Binghe Xu with the “2024 Annual Achievement Award” in…
Connecting Medical Expertise through Media